Improved liver function in patients with cirrhosis due to chronic hepatitis C virus who achieve sustained virologic response is not accompanied by increased liver volume.
Adult
Aged
Aged, 80 and over
Antiviral Agents
/ therapeutic use
Carcinoma, Hepatocellular
/ complications
Female
Hepacivirus
/ drug effects
Hepatitis C, Chronic
/ complications
Humans
Liver
/ drug effects
Liver Cirrhosis
/ complications
Liver Neoplasms
/ complications
Male
Middle Aged
Organ Size
/ drug effects
Retrospective Studies
Sustained Virologic Response
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
12
2019
accepted:
01
04
2020
entrez:
21
4
2020
pubmed:
21
4
2020
medline:
16
7
2020
Statut:
epublish
Résumé
Serum albumin level improves in patients with chronic hepatitis C virus (HCV) infection who achieve sustained virologic response (SVR) with antiviral therapy. However, it remains controversial whether liver volume increases along with SVR. Patients with chronic HCV infection with a history of hepatocellular carcinoma (HCC) who achieved SVR with anti-HCV treatment from March 2003 to November 2017 were enrolled. Patients were followed up with periodic computed tomography (CT) scans to detect HCC recurrence. Patients who underwent treatment for HCC recurrence within 1 year after initiation of anti-HCV treatment were excluded. Laboratory data, including alanine aminotransferase (ALT) level, serum albumin level, and platelet count, were collected at baseline and timepoints after treatment initiation. Liver volume was evaluated at baseline and 24 and 48 weeks after treatment initiation using a CT volume analyzer. A linear mixed-effects model was applied to analyze the chronologic change in liver volume. The correlations between changes in ALT level, albumin level, and liver volume were also evaluated. Of 108 enrolled patients, 78 had cirrhosis. Serum albumin level continued to increase through 48 weeks after treatment initiation. A significant increase in liver volume was observed only in patients without cirrhosis (P = 0.005). There was a significant correlation between ALT level decrease and albumin level increase (P = 0.018). Improved liver albumin production with SVR was contributed by improved liver cell function rather than increased liver volume in patients with cirrhosis.
Sections du résumé
BACKGROUND
Serum albumin level improves in patients with chronic hepatitis C virus (HCV) infection who achieve sustained virologic response (SVR) with antiviral therapy. However, it remains controversial whether liver volume increases along with SVR.
METHODS
Patients with chronic HCV infection with a history of hepatocellular carcinoma (HCC) who achieved SVR with anti-HCV treatment from March 2003 to November 2017 were enrolled. Patients were followed up with periodic computed tomography (CT) scans to detect HCC recurrence. Patients who underwent treatment for HCC recurrence within 1 year after initiation of anti-HCV treatment were excluded. Laboratory data, including alanine aminotransferase (ALT) level, serum albumin level, and platelet count, were collected at baseline and timepoints after treatment initiation. Liver volume was evaluated at baseline and 24 and 48 weeks after treatment initiation using a CT volume analyzer. A linear mixed-effects model was applied to analyze the chronologic change in liver volume. The correlations between changes in ALT level, albumin level, and liver volume were also evaluated.
RESULTS
Of 108 enrolled patients, 78 had cirrhosis. Serum albumin level continued to increase through 48 weeks after treatment initiation. A significant increase in liver volume was observed only in patients without cirrhosis (P = 0.005). There was a significant correlation between ALT level decrease and albumin level increase (P = 0.018).
CONCLUSIONS
Improved liver albumin production with SVR was contributed by improved liver cell function rather than increased liver volume in patients with cirrhosis.
Identifiants
pubmed: 32310974
doi: 10.1371/journal.pone.0231836
pii: PONE-D-19-35703
pmc: PMC7170262
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0231836Déclaration de conflit d'intérêts
I have read the journal’s policy and the authors of this manuscript have the following competing interests: We confirm that the following Competing Interests statement is both true and correct for our work. Ryosuke Tateishi - Speaking and Teaching: Gilead Sciences Co., Ltd., MSD K. K. Kazuhiko Koike - Speaking and Teaching: Gilead, MSD, AbbVie. The following authors have nothing to disclose: Taijiro Wake, Tsuyoshi Fukumoto, Ryo Nakagomi, Mizuki Nishibatake Kinoshita, Takuma Nakatsuka, Masaya Sato, Tatsuya Minami, Koji Uchino, Kenichiro Enooku, Hayato Nakagawa, Hidetaka Fujinaga, Yoshinari Asaoka, Yasuo Tanaka, Motoyuki Otsuka.
Références
J Gastroenterol Hepatol. 2005 Dec;20(12):1843-9
pubmed: 16336442
J Gastroenterol. 2018 Apr;53(4):557-565
pubmed: 28948366
Ann Intern Med. 1992 Jan 15;116(2):97-102
pubmed: 1309286
Dig Dis Sci. 1994 Feb;39(2):240-4
pubmed: 8313804
J Clin Exp Hepatol. 2016 Mar;6(1):15-20
pubmed: 27194891
Lancet. 1997 Mar 22;349(9055):825-32
pubmed: 9121257
J Hepatobiliary Pancreat Sci. 2014 Apr;21(4):235-8
pubmed: 24520049
J Viral Hepat. 1997 Mar;4(2):81-91
pubmed: 9097263
Transplant Proc. 2012 Mar;44(2):338-40
pubmed: 22410010
Br J Radiol. 2016;89(1059):20150896
pubmed: 26765832
Ann Intern Med. 2005 Jan 18;142(2):105-14
pubmed: 15657158
Abdom Radiol (NY). 2017 Feb;42(2):460-467
pubmed: 27604894
Hepatology. 1993 Jul;18(1):79-85
pubmed: 8392029
Br J Surg. 2001 Feb;88(2):165-75
pubmed: 11167863
AJR Am J Roentgenol. 2007 Sep;189(3):W153-9
pubmed: 17715084
Ann Intern Med. 2000 Apr 4;132(7):517-24
pubmed: 10744587
Br J Surg. 2001 Aug;88(8):1084-91
pubmed: 11488794
Clin Gastroenterol Hepatol. 2007 Apr;5(4):502-7
pubmed: 17261383
Gastroenterology. 2012 May;142(6):1264-1273.e1
pubmed: 22537432
Hepatol Res. 2015 Oct;45(10):E99-E107
pubmed: 25559860
Clin Gastroenterol Hepatol. 2010 Feb;8(2):192-9
pubmed: 19879972
Hepatology. 2007 Jul;46(1):32-6
pubmed: 17567829
J Clin Invest. 1987 Jun;79(6):1635-41
pubmed: 3584463
Hepatology. 1995 May;21(5):1317-21
pubmed: 7737637
Ann Surg. 1998 Feb;227(2):269-74
pubmed: 9488526
Gut. 2004 Mar;53(3):425-30
pubmed: 14960528
J Gastroenterol. 2018 Apr;53(4):566-575
pubmed: 29052790
Hepatology. 2018 Feb;67(2):505-513
pubmed: 28865152
Hepatology. 2010 Oct;52(4):1193-200
pubmed: 20658462
Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):122-132
pubmed: 27924080
Aliment Pharmacol Ther. 2015 Oct;42(7):889-901
pubmed: 26250762